You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com
 Google Custom Search

SCH 532706

A phase I study to explore the activity and safety of SCH 532706, a small molecule chemokine receptor-5 (CCR5) antagonist in HIV-1 infected subjects
- 2/05/08


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
 non Nucleoside Reverse
  Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
 Entry / Fusion Inhibitors EIs
Integrase Inhibitors
Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
 Metabolic Complications
Lipodystrophy - Fat Redistribution
 Treatment Guidelines
Women/Children